Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double‐blind studies
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine:
post hoc
analyses of three randomized double‐blind studies
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF NEUROLOGY
Volume 27, Issue 3, Pages 542-549
Publisher
Wiley
Online
2019-10-09
DOI
10.1111/ene.14102
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
- (2018) Vladimir Skljarevski et al. CEPHALALGIA
- Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study
- (2018) Messoud Ashina et al. CEPHALALGIA
- Calcitonin-gene-related peptide pathway mAbs and migraine prevention
- (2018) Koen Paemeleire et al. CURRENT OPINION IN NEUROLOGY
- OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine
- (2018) James E. Frampton et al. DRUGS
- The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine Therapy
- (2018) Bianca Raffaelli et al. Neurotherapeutics
- Cycling Through Migraine Preventive Treatments: Implications for All-Cause Total Direct Costs and Disease-Specific Costs
- (2018) Janet H. Ford et al. Journal of Managed Care & Specialty Pharmacy
- Galcanezumab in chronic migraine
- (2018) Holland C. Detke et al. NEUROLOGY
- Migraine Prophylaxis and Acute Treatment Patterns Among Commercially Insured Patients in the United States
- (2017) J. Michael Woolley et al. HEADACHE
- Antibodies to watch in 2017
- (2016) Janice M. Reichert mAbs
- The International Classification of Headache Disorders, 3rd edition (beta version)
- (2013) CEPHALALGIA
- Patterns of Use and Reasons for Discontinuation of Prophylactic Medications for Episodic Migraine and Chronic Migraine: Results From the Second International Burden of Migraine Study (IBMS-II)
- (2013) Andrew M. Blumenfeld et al. HEADACHE
- Rates and reasons for discontinuation of triptans and opioids in episodic migraine: Results from the American Migraine Prevalence and Prevention (AMPP) study
- (2013) Starr Holland et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Table 1
- (2012) S.D. Silberstein et al. NEUROLOGY
- OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial
- (2010) SK Aurora et al. CEPHALALGIA
- OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial
- (2010) HC Diener et al. CEPHALALGIA
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started